In recent months, the medical cannabis market in Israel has undergone significant upheavals and changes. The war and its damages have led to a tremendous increase in demand for licenses issuing and the need to receive cannabis response fast.

At the same time, regulatory changes promoted by legislators to ease the regulatory bureaucracy, which burdened both businesses and patients alike, signify and indicate a positive trend towards facilitating and easing a market that has suffered enough.

Given the new regulations and on the eve of the transition from licenses to prescriptions, an article was published in “The Times of Israel” which review these trends from various perspectives.

You are invited to read the opinion of Adi Rozenfeld, a partner in Herzog and head of the cannabis desk, who participated the article.